Journal of Complementary and Alternative Medical Research

Rasa Shastra, the branch of Ayurveda concerned with the medicinal use of metals, minerals and processed mercury, occupies a contested position between an ancient iatrochemical tradition and contemporary pharmaceutical science. Its principal dosage forms, the incinerated herbo-mineral preparations known as bhasma and the mercurial kajjali and rasa products, are simultaneously described by practitioners as safe, potent and fast-acting, and by clinical toxicologists as recurrent sources of lead, mercury and arsenic poisoning. This review critically synthesises the evidence base connecting the classical iatrochemical operations of purification, incineration and trituration to modern understanding of particle formation, chemical speciation and toxicity. It examines the widely cited claim that bhasma constitutes an early form of nanomedicine, the argument that chemical form rather than elemental content determines toxicity, and the tension between mechanistic plausibility and demonstrated clinical benefit. The available evidence indicates that carefully controlled processing can convert reactive metals into poorly soluble sulphide or oxide phases of nanometric to submicron dimension, and that the most studied mercurial preparation, rasasindura, is a robust single-phase mercuric sulphide rather than free mercury. The evidence is far weaker, however, for the inference that structural stability guarantees clinical safety, and weakest of all for therapeutic efficacy, which rests largely on preclinical models and uncontrolled observation. Persistent problems include batch-to-batch variability, absence of enforced processing standards, reliance on animal and cell-line data of uneven quality, and a documented stream of poisoning cases traceable to inadequately processed or contaminated products. The field would benefit from mandatory speciation-based quality control, harmonised pharmacopoeial standards, transparent pharmacovigilance and adequately powered clinical trials that report chemical characterisation alongside outcomes. Until such evidence exists, confident claims of either uniform safety or established efficacy remain premature, and the reconciliation of Rasa Shastra with modern pharmaceutical science is best regarded as an open and empirically demanding question.